Skip to main content

Table 3 Number of second perimenopausal symptoms after HSCT and RR at 95% CI (patients with GnRHa treatment or without it)

From: Gonadotropin-releasing hormone agonist for the preservation of ovarian function in survivors of haematopoietic stem cell transplantation for haematological diseases

 

GnRHa(107)

Control(204)

RR(95%CI)a

P

Perimenopausal symptoms

 Yes

67(62.62)

152(74.51)

1.47(1.05–2.06)

0.027

  Hot flashes

39

93

  

  Mood swings

48

92

  

  Sleep disturbance

20

60

  

  Sexual dysfunction

18

54

  

  Joint/muscle pain

2

19

  

  Dysuria/urinary frequency

1

4

  

No

40(37.38)

52(25.49)

  
  1. aThe difference remained statistically significant after adjusting for factors. (RR: 1.488, 95% CI: 1.055–2.098, P = 0.024), adjusted for conventional chemotherapy prior to the myeloablative regimen for HSCT; (RR: 1.44, 95% CI: 1.02–2.02, P = 0.036), adjusted for TBI exposure; (RR: 1.46, 95% CI: 1.04–2.06, P = 0.031), adjust for above two factors simultaneously
Back to article page

BMC Women's Health

ISSN: 1472-6874

Contact us